Prognostic value of the prognostic immune-inflammatory-nutritional score in patients with advanced gastric cancer treated with immunochemotherapy

Table 5 Univariate and multivariate analyses of prognostic factors for overall survival

Variables	Univariate		Multivariate
	P value	HR (95%CI)	P value	HR (95%CI)
Gender
Male vs female	0.941	0.98 (0.63-1.54)	0.182	1.38 (0.86-2.21)
Age (years)
≥ 60 vs < 60	0.295	1.29 (0.80-2.06)	0.781	1.07 (0.67-1.70)
BMI (kg/m2)
< 25 vs ≥ 25	0.348	0.73 (0.38-1.41)
CEA (ng/mL)
< 3 vs ≥ 3	0.231	1.31 (0.84-2.02)
CA199 (ng/mL)
< 37 vs ≥ 37	0.200	1.33 (0.86-2.06)
PIIN score
< 25.69 vs ≥ 25.69	< 0.001	2.75 (1.57-4.83)	0.013	2.09 (1.17-3.75)
ECOG
0 vs 1	0.002	2.20 (1.33-3.61)	0.033	1.76 (1.05-2.95)
TNM staging
III vs IV	< 0.001	3.20 (1.98-5.16)	< 0.001	2.77 (1.62-4.75)
Peritoneal metastasis
No vs yes	0.173	1.35 (0.88-2.09)
Liver metastasis
No vs yes	0.008	1.90 (1.18-3.05)
PD-L1 expression
CPS < 5 vs CPS ≥ 5	< 0.001	0.25 (0.16-0.41)	< 0.001	0.41 (0.25-0.69)
MMR status
pMMR vs dMMR	< 0.001	0.30 (0.16-0.58)	0.003	0.37 (0.19-0.72)

BMI: Body mass index; CEA: Carcinoembryonic-antigen; CA199: Carbohydrate antigen 199; PIIN score: Prognostic immune-inflammatory-nutritional score; ECOG: Eastern Cooperative Oncology Group; PD-L1: Programmed death-ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair; HR: Hazard ratio.